Science - Academic Societies
Kevin J. Scanlon was President of the International Society for Cancer Gene Therapy from 2001-2003
The International Society for Cancer Gene Therapy (ISCGT) is the first worldwide society to represent the field of gene therapy, and it is the only society to focus exclusively on the study of improving the treatment of patients with cancer by gene therapy.
The goal of the society is to rapidly disseminate scientific information on novel methods and technologies in the gene therapy field for the treatment of human disease. To facilitate this process, the society supports the following areas: a website for the society, the journal Cancer Gene Therapy, international conferences on cancer gene therapy, and webcasts of the meetings via the society’s website.
Many changes have been witnessed in the gene therapy field since its inception. There have been some successes but also some setbacks, as can be expected in any new endeavor. Our mission for the society is to aid in the communication of these rapidly changing advances and to be the most efficient vehicle to maximize the dissemination of this scientific information to the scientific community. The benefits of this strategy will be the improved treatment of patients with cancer worldwide. Cancer is not a regional disease, and its cure will require a worldwide effort. The ISCGT’s role is to help facilitate this new gene therapy and genomic scientific research by exploiting the new digital communication revolution.
Professor Kevin J. Scanlon
ISCGT President, (2001-2003)
Co-Editor, Cancer Gene Therapy, (1993-present)
Kevin J. Scanlon is a member of the American Association for Cancer Research (AACR) for the past 25 years.
This professional society of more than 24,000 laboratory and clinical scientists engaged in basic, translational, and clinical cancer research in the United States and more than 60 other countries. Founded in 1907, the AACR has as its mission to accelerate the prevention and cure of cancer through research, education, communication, collaboration and advocacy. The AACR convenes an Annual Meeting attended by more than 15,000 scientists from around the world who share new and significant discoveries in the cancer field. Specialty meetings throughout the year focus on all the important areas of basic, translational, and clinical cancer research.www.aacr.org
Kevin J. Scanlon is a member of the American Society of Gene Therapy (ASGT) for the past eight years.
This is the largest medical professional organization representing researchers and scientists dedicated to discovering new gene therapies. The Society was established in 1996 and has already grown to almost 3,000 members. ASGT is committed to promoting and fostering the exchange and dissemination of information and ideas related to gene therapy, encouraging the general field of research involving gene therapy and promoting professional and public education in all areas of gene therapy. ASGT holds an annual meeting each year, featuring scientific symposia, workshops, oral abstract presentations, exhibits and poster sessions.www.asgt.org
|Top of Page|